Display options
Cite
Pyykkő I, Manchaiah V, Levo H, et al. Impact evaluation and association with EuroQol 5D health-related utility values in Ménière's disease. Springerplus. 2015;4:717doi: 10.1186/s40064-015-1527-0.
Pyykkő, I., Manchaiah, V., Levo, H., & Kentala, E. (2015). Impact evaluation and association with EuroQol 5D health-related utility values in Ménière's disease. SpringerPlus, 4717. https://doi.org/10.1186/s40064-015-1527-0
Pyykkő, Ilmari, et al. "Impact evaluation and association with EuroQol 5D health-related utility values in Ménière's disease." SpringerPlus vol. 4 (2015): 717. doi: https://doi.org/10.1186/s40064-015-1527-0
Pyykkő I, Manchaiah V, Levo H, Kentala E. Impact evaluation and association with EuroQol 5D health-related utility values in Ménière's disease. Springerplus. 2015 Nov 24;4:717. doi: 10.1186/s40064-015-1527-0. eCollection 2015. PMID: 26636005; PMCID: PMC4656266.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2015 Nov 24;4:717. doi: 10.1186/s40064-015-1527-0. eCollection 2015.

Impact evaluation and association with EuroQol 5D health-related utility values in Ménière's disease.

SpringerPlus

Ilmari Pyykkő, Vinaya Manchaiah, Hilla Levo, Erna Kentala

Affiliations

  1. Department of Otolaryngology, University of Tampere, Tampere, Finland.
  2. Department of Speech and Hearing Sciences, Lamar University, Beaumont, TX USA ; Department of Behavioural Sciences and Learning, The Swedish Institute for Disability Research, Linköping University, Linköping, Sweden ; Audiology India, Mysore, Karnataka India.
  3. Department of Otolaryngology, University of Helsinki, Helsinki, Finland.

PMID: 26636005 PMCID: PMC4656266 DOI: 10.1186/s40064-015-1527-0

Abstract

The study was aimed at evaluating the validity of impact measures among patients with Ménière's disease (MD) with outcome variables of EuroQol generic health-related quality of life (HRQoL) measures (i.e., EQ-5D) by using Visual Analogue Scale (VAS) and EQ-5D index values. 183 members (out of 200 contacted) of the Finish Ménière Association returned the questionnaires that they had filled out. Various open-ended and structured questionnaires focusing on diagnostic aspects of symptoms and impairment caused by the disease were used. For activity limitation and participation restriction, standardized questionnaires were used. Open-ended questions on impact of the disease were asked, and subsequently classified based on the WHO-ICF classification. The general HRQoL was evaluated with EQ-5D index value and EQ VAS instruments. Correlation and linear regression analyses were used to explore the association between HRQoL and other aspects. Based on the explanatory power of different models the disease specific semeionic model provides the most accurate prediction in EQ-5D index calculations (38 % of the variance explained). In EQ VAS scores, HRQoL is most accurately determined by participation restriction (53 % of the variance explained), but the worst prediction was in ICF-based limitations (8 % of the variance explained). Interestingly, attitude and personal trait explained the reduction of HRQoL somewhat better than ICF-based variables. Activity limitation and participation restrictions are significant components of MD, but are less frequently recognized as significant factors in self-evaluating the effect of MD on the quality of life. The current study results suggest that MD patients seem to have problem identifying factors causing activity limitation and participation restrictions and hence use the semiotic description focusing on complaints.

Keywords: Activity limitations; EQ-5D; EuroQol; ICF; Ménière’s disease; Participation restrictions; Quality of life

References

  1. Ann Med. 2001 Jul;33(5):337-43 - PubMed
  2. Br Med J (Clin Res Ed). 1985 Aug 3;291(6491):326-9 - PubMed
  3. Am J Otol. 1997 Jan;18(1):67-73 - PubMed
  4. Auris Nasus Larynx. 2012 Oct;39(5):469-74 - PubMed
  5. Health Econ. 2005 Mar;14(3):217-30 - PubMed
  6. Int J Audiol. 2010 Nov;49(11):839-43 - PubMed
  7. Br J Audiol. 1994 Dec;28(6):299-311 - PubMed
  8. Value Health. 2007 Jul-Aug;10(4):273-84 - PubMed
  9. Clin Rehabil. 2003 Jul;17(4):349-54 - PubMed
  10. Laryngoscope. 2007 Sep;117(9):1622-8 - PubMed
  11. Am J Otol. 1996 Nov;17(6):883-92 - PubMed
  12. J Soc Psychol. 1986 Apr;126(2):213-25 - PubMed
  13. Int J Rehabil Res. 2012 Sep;35(3):197-202 - PubMed
  14. Ann Med. 2001 Jul;33(5):323-7 - PubMed
  15. Otol Neurotol. 2007 Jan;28(1):74-86 - PubMed
  16. Otol Neurotol. 2001 Nov;22(6):888-94 - PubMed
  17. Qual Life Res. 1999 Aug;8(5):447-59 - PubMed
  18. Otol Neurotol. 2015 Jun;36(5):854-61 - PubMed
  19. Ann Med Health Sci Res. 2014 Jan;4(1):3-7 - PubMed
  20. J Psychosom Res. 1992 Dec;36(8):731-41 - PubMed
  21. Otol Neurotol. 2002 Nov;23(6):941-8 - PubMed
  22. Otol Neurotol. 2010 Feb;31(2):335-8 - PubMed
  23. Otol Neurotol. 2004 May;25(3):339-44 - PubMed
  24. Clin Otolaryngol. 2013 Apr;38(2):170-4 - PubMed
  25. Ann Otol Rhinol Laryngol. 2010 Sep;119(9):583-9 - PubMed
  26. Clin Otolaryngol Allied Sci. 2003 Oct;28(5):436-41 - PubMed

Publication Types